Global prevention strategies for type 2 diabetes must pivot away from managing established dysglycemia and instead target prediabetes remission and the restoration of normoglycemia through life-course interventions, precision tools, and addressing underlying mechanistic differences, according to recent medical analyses.
This medical focus coincides with a broader international push. According to the United Nations, more than 800 million people worldwide live with diabetes, a total four times higher than in 1990, with the steepest increases concentrated in low- and middle-income nations where early detection remains difficult to access.
While premature mortality rates from several other major noncommunicable diseases are declining, deaths attributed to diabetes continue to climb. The condition remains a leading contributor to lost healthy life years globally, according to United Nations figures.
Understanding the Global Scale and the WHO Response
The World Health Organization classifies diabetes into three main categories. Type 1 diabetes is most common among children and adolescents, requiring daily insulin injections for survival, while type 2 diabetes typically develops silently in adults and older populations. Additionally, diabetes in pregnancy—encompassing both pre-existing conditions and gestational diabetes—affects more than one in six pregnancies, elevating health risks for both mother and child and increasing the likelihood of developing type 2 diabetes later in life.
To combat rising rates, the World Health Organization launched the Global Diabetes Compact in 2021 to expand equitable access to care and treatment. In 2022, WHO Member States endorsed five specific global targets to achieve by 2030:
- Diagnosing 80 percent of all people living with diabetes
- Ensuring good glycemic control for 80 percent of diagnosed individuals
- Achieving blood pressure control for 80 percent of diagnosed individuals
- Providing statins to 60 percent of diabetes patients aged 40 or older
- Providing 100 percent of people with type 1 diabetes access to affordable insulin and blood-glucose self-monitoring tools
According to United Nations reporting, achieving these benchmarks requires strengthening health systems to support early diagnosis and continuous care across every stage of human development.
A Life-Course Approach to Prevention and Care
Adopting a life-course strategy means recognizing that each stage of life presents distinct medical risks and intervention opportunities. In early life, prompt diagnosis and management of type 1 diabetes are essential to prevent fatal complications. During childhood, supportive school and community environments help mitigate type 2 diabetes risk factors.
During reproductive years, integrating regular diabetes screening into maternal health services allows for earlier detection. For example, the World Health Organization introduced formal guidance on caring for women with diabetes during pregnancy, creating a framework to address noncommunicable diseases during this critical window.
At working age, when type 2 diabetes frequently progresses without obvious symptoms, early screening and preventive measures remain crucial. Healthcare systems are increasingly urged to deploy scalable precision tools to identify metabolic shifts before full-scale dysglycemia takes root.
Next Steps and Future Implementation
As international health agencies continue working toward the 2030 targets, national health authorities are tasked with expanding screening infrastructure, particularly in resource-limited settings where diagnostic gaps are widest. Public health updates and policy frameworks regarding the Global Diabetes Compact are available through official channels at the World Health Organization.
Have thoughts on this life-course approach to diabetes prevention? Share this article or leave a comment below.
Keep reading